MIS Stock Chart & Stats
€0.44
>-€0.01(-0.68%)
At close: 4:00 PM EST
€0.44
>-€0.01(-0.68%)
Day’s Range― - ―
52-Week Range€0.32 - €0.48
Previous CloseN/A
Volume0.00
Average Volume (3M)349.00
Market Cap
€166.76M
Enterprise Value€552.61M
Total Cash (Recent Filing)€8.14M
Total Debt (Recent Filing)€281.81M
Price to Earnings (P/E)18.3
Beta1.01
Next Earnings
Aug 24, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.04
Shares Outstanding389,634,830
10 Day Avg. Volume805
30 Day Avg. Volume349
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.12
Price to Sales (P/S)1.01
P/FCF Ratio588.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.48Price Target Upside8.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.03
Revenue Forecast (FY)€165.63M
Bulls Say, Bears Say
Bulls Say
Recent Revenue IncreaseA 74.5% revenue rise indicates durable demand growth and stronger clinic utilization. Sustained top-line expansion supports scale benefits across clinics and labs, enabling reinvestment in capacity and clinical services that drive long-term competitive positioning and revenue resilience.
Healthy Profit MarginsConsistently healthy gross and net margins for a service-led fertility business reflect pricing power and operational efficiencies in clinics and labs. These margins underpin sustainable profitability, fund R&D/clinical quality, and provide cushion during reimbursement or volume fluctuations.
Balanced Capital Structure & ROEA moderate leverage profile with a 0.73 D/E and 10.2% ROE signals prudent financing and efficient equity use. This balance supports continued clinic investment or M&A while keeping financial flexibility intact, helping the business fund growth without excessive refinancing risk.
Bears Say
Severe Free Cash Flow DeclineA near-total drop in free cash flow is a structural concern: it limits the firm's ability to fund capex, maintain dividends, or absorb shocks without external financing. If persistent, it can force asset sales, equity raises, or higher leverage, weakening long-term stability.
Low Cash ConversionOnly 21% of net income converted to operating cash indicates weak earnings quality or working capital strain. Persistent low conversion impairs internal funding for growth and increases reliance on debt or equity, raising financing risk and limiting durable free cash flow generation.
Margin VolatilityVolatile operating margins undermine forecasting and capital allocation in a service business tied to treatment volumes and reimbursement. If margin swings persist, they can disrupt reinvestment plans, staffing, and profitability sustainability across clinic networks over the medium term.
Monash IVF Group Ltd News
MIS FAQ
What was Monash IVF Group Ltd’s price range in the past 12 months?
Monash IVF Group Ltd lowest stock price was €0.32 and its highest was €0.48 in the past 12 months.
What is Monash IVF Group Ltd’s market cap?
Monash IVF Group Ltd’s market cap is €166.76M.
When is Monash IVF Group Ltd’s upcoming earnings report date?
Monash IVF Group Ltd’s upcoming earnings report date is Aug 24, 2026 which is in 45 days.
How were Monash IVF Group Ltd’s earnings last quarter?
Monash IVF Group Ltd released its earnings results on Feb 25, 2026. The company reported €0.011 earnings per share for the quarter, missing the consensus estimate of €0.015 by -€0.004.
Is Monash IVF Group Ltd overvalued?
According to Wall Street analysts Monash IVF Group Ltd’s price is currently Undervalued.
Does Monash IVF Group Ltd pay dividends?
Monash IVF Group Ltd does not currently pay dividends.
What is Monash IVF Group Ltd’s EPS estimate?
Monash IVF Group Ltd’s EPS estimate is 0.01.
How many shares outstanding does Monash IVF Group Ltd have?
Monash IVF Group Ltd has 389,634,830 shares outstanding.
What happened to Monash IVF Group Ltd’s price movement after its last earnings report?
Monash IVF Group Ltd reported an EPS of €0.011 in its last earnings report, missing expectations of €0.015. Following the earnings report the stock price went down -0.508%.
Which hedge fund is a major shareholder of Monash IVF Group Ltd?
Currently, no hedge funds are holding shares in DE:MIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Monash IVF Group Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€0.48 (8.37% Upside)
€0.48 (8.37% Upside)
Blogger Sentiment
Bullish
DE:MIS Sentiment 100%
Sector Average 69%
Sector Average 69%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-37.39%
12-Months-Change
Fundamentals
Return on Equity
6.06%
Trailing 12-Months
Asset Growth
0.49%
Trailing 12-Months
Company Description
Monash IVF Group Ltd
Founded in 2014 and headquartered in Richmond, Australia, Monash IVF Group Limited delivers specialized reproductive assistance and women's imaging services. Its operations span Australia and Malaysia, offering a broad spectrum of care. This includes diagnostic obstetric and gynecological ultrasound examinations, a range of fertility treatments, and advanced tertiary-level prenatal diagnostics. The company is also a key provider of in-vitro fertilization (IVF) services.
MIS Stock 12 Month Forecast
Average Price Target
€0.48
▲(8.37% Upside)
Technical Analysis
Genetic Technologies
―
Healius Limited
―
Cryosite Limited
―
Sonic Healthcare Limited
―
Australian Clinical Labs Ltd
―
Options Prices
Currently, No data available
---